Results 181 to 190 of about 28,689 (318)

Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model [PDF]

, 2017
Saad S. Kenderian, Marco Ruella, Olga Shestova, Miriam Kim, Michael Klichinsky, Fang Chen, Natalka Kengle, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar Gill   +10 more
openalex   +1 more source

Ruxolitinib for essential thrombocythemia?

Oncoscience, 2017
Srdan Verstovsek, Prithviraj Bose
openaire   +3 more sources

PACLseq: A Standalone Diagnostic Method for Ph‐Like Acute Lymphoblastic Leukemia Using Nanopore Sequencing

MedComm, Volume 6, Issue 10, October 2025.
PACLseq has demonstrated reliable detection results with a sensitivity of 93.33% and specificity of 100%, along with a short turnaround time, cost‐effectiveness, a streamlined workflow, and resilience towards poor RNA quality and small sample input.
Hang Zhang, Huan Yu, Yanmei Chen, Kai Jiang, Beibei Huo, Jialin Li, Ting Liu, Dan Xie   +7 more
wiley   +1 more source

Pulmonary arterial hypertension exacerbated by ruxolitinib [PDF]

, 2015
Harrison, C, Howard, L, Low, AT, Tulloh, RMR   +3 more
core   +2 more sources

Liver Injury Resolution after Ruxolitinib Treatment in Newly Diagnosed Primary Myelofibrosis [PDF]

, 2017
Valentín García‐Gutiérrez
openalex   +1 more source

Hypertrophic Scarring and Keloids: Epidemiology, Molecular Pathogenesis, and Therapeutic Interventions

MedComm, Volume 6, Issue 10, October 2025.
Hypertrophic scars and keloids highlight distinct epidemiology, multifactorial triggers (genetic, mechanical, medical), and dysregulated signaling hubs (TGF‐β, Integrin‐FAK, Wnt/β‐catenin). Emerging interventions targeting fibroblast plasticity, inflammation, and biomechanics via gene editing, immune modulation, and biomaterials are increasingly ...
Xiaowan Fang, Yuxiang Wang, Hao Chen, Zhenzhen Yan, Shunxin Jin, Yixin Wu, Futing Shu, Shichu Xiao   +7 more
wiley   +1 more source

Targeting the Ubiquitin–Proteasome System for Cancer

MedComm, Volume 6, Issue 10, October 2025.
This figure shows the mechanism of protein degradation by ubiquitin–proteasome system. The process begins with ubiquitin activation by the E1 enzyme, forming a thioester bond between E1's cysteine residue and ubiquitin's glycine carboxyl group, powered by ATP hydrolysis.
Zhaoyun Liu, Jiao Lai, Ziyu Ma, Jianhua Pan, Chun Yang, Rong Fu   +5 more
wiley   +1 more source

Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis

, 2015
Renato Tavares Daher, Giuseppe A. Palumbo, Philipp le Coutre, Francesca Palandri, Haifa Kathrin Al‐Ali, Bruno Martino, Anna Marina Liberati, José María Grasa, Massimo Breccia, David Brittain, Lynda Foltz, Martin Grießhammer, Pia Raanani, Vikas Gupta, Pilar Giraldo, Jagannath Ghosh, Bayane Tannir, Julian Perez Ronco, Alessandro M. Vannucchi   +18 more
openalex   +1 more source

Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome [PDF]

, 2017
Enes Coşkun, Sue Height, Anil Dhawan, Nedim Hadžić   +3 more
openalex   +1 more source

Role of ruxolitinib in preventing cardiac arrhythmias: A pooled analysis of clinical studies in hematology. [PDF]

Int J Cardiol Heart Vasc
Zaoli S, Khatri M, Holzhauer B, Peyrard S, Ferreira A, Stefanelli T.   +5 more
europepmc   +1 more source